Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not been reported separately, raising concerns about safety and efficacy in this subgroup.
Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial / Wang, Yongjun; Pan, Yuesong; Li, Hao; Amarenco, Pierre; Denison, Hans; Evans, Scott R; Himmelmann, Anders; James, Stefan; Birve, Filip; Ladenvall, Per; Molina, Carlos A; Johnston, ; S, Claiborne; Toni, D. - In: JAMA NEUROLOGY. - ISSN 2168-6149. - (2021). [10.1001/jamaneurol.2021.2440]
Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial
Toni D
2021
Abstract
Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not been reported separately, raising concerns about safety and efficacy in this subgroup.| File | Dimensione | Formato | |
|---|---|---|---|
|
Wang_Efficacy and Safety of Ticagrelor and Aspirin_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
352.58 kB
Formato
Adobe PDF
|
352.58 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
